NMS·Healthcare·$483M·#119 / 520 in Healthcare
RGNX REGENXBIO Inc.
62SOLID
CATEGORY BREAKDOWN
GROWTH100
QUALITY74
STABILITY16
VALUATION91
GOVERNANCE63
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+104.5%
100
> 50% strong
Gross Margin
Revenue retained after direct costs
88.1%
100
> 50% strong
Cash Runway
Months of cash at current burn rate
3 months
6
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
71.5%
36
< 25% strong
Price / Sales
Market cap relative to trailing revenue
2.8x
91
< 3x strong
Rule of 40
Growth rate plus operating margin
10
35
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
7.8%
54
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+3.0%
82
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE RGNX WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when RGNX's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.